GHRP-6 vs Tesofensine
Head-to-head comparison of GHRP-6 and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Ghrp 6 | Tesofensine |
|---|---|---|
| Category | Growth Hormone Secretagogue | Weight Loss / Reuptake Inhibitor |
| Mechanism | GHRP-6 functions as a synthetic ghrelin mimetic by binding to GHS-R1a in the pituitary and hypothalamus, triggering pulsatile GH release and raising IGF-1 levels. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | D — Preclinical | C — Phase II–III Clinical Trials |
| Clinical Status | Research-only / Not approved for human use | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Intense hunger due to ghrelin receptor activation (more pronounced than other GH secretagogues); Transient mild increases in cortisol and ACTH (typically not clinically significant) | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~873.0 g/mol | ~397.5 g/mol |
| Half-Life | ~15–60 minutes | N/A |
Overview
GHRP-6 and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
GHRP-6 — Mechanism & Evidence
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a). It stimulates pulsatile GH release from the pituitary while maintaining physiological feedback controls. It is one of the earliest GH-releasing peptides developed and is notable for strong appetite stimulation via ghrelin receptor activation. Beyond endocrine effects, GHRP-6 exhibits cytoprotective properties through the CD36 receptor, with preclinical data showing cardioprotective, neuroprotective, and anti-fibrotic effects.
Key claims: Increases growth hormone levels; Stimulates appetite; Cytoprotective and tissue-protective effects.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. GHRP-6 focuses on Body Composition, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
GHRP-6: Intense hunger due to ghrelin receptor activation (more pronounced than other GH secretagogues) Transient mild increases in cortisol and ACTH (typically not clinically significant) Water retention and bloating reported
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.